Ramon Leon, MD
Family Medicine · Miami, FLNPI 1073694337
Payments from drug & device makers
Across 536 payments — averaging $11,757 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1.6M
- AbbVie$1.3M
- Eli Lilly$1M
- E.r. Squibb & Sons, L.L.C.$945K
- Gilead$311K
- Novo Nordisk AS$222K
- plus $932K from 31 others
Across 18 payments — averaging $9658.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$123K
- Eli Lilly$51K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 63 | $1,575,906 |
| AbbVie(2 entities) | 61 | $1,313,854 |
| Eli Lilly | 22 | $1,002,098 |
| E.r. Squibb & Sons, L.L.C. | 16 | $944,670 |
| Gilead | 22 | $311,409 |
| Novo Nordisk AS | 68 | $221,783 |
| Hikma Pharmaceuticals USA | 9 | $217,569 |
| Partner Therapeutics, Inc. | 14 | $198,910 |
| Chiesi USA, Inc. | 54 | $140,708 |
| AstraZeneca | 27 | $97,508 |
| Sanofi US Services Inc. | 17 | $75,188 |
| Roche Products Limited | 7 | $70,517 |
| Eisai Inc. | 10 | $57,533 |
| Boehringer Ingelheim | 7 | $28,084 |
| F. Hoffmann-la Roche AG | 4 | $21,894 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 3 | $10,015 |
| Biogen | 1 | $8,820 |
| Boehringer Ingelheim International GmbH | 12 | $2,578 |
| Teva Pharmaceuticals USA, Inc. | 7 | $614 |
| Pfizer | 22 | $434 |
| Novo Nordisk | 21 | $433 |
| Lilly USA, LLC | 20 | $342 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $219 |
| Astellas Pharma US Inc | 5 | $173 |
| Abbott | 6 | $109 |
| Bayer | 5 | $107 |
| Amarin Pharma, Inc. | 5 | $79 |
| Idorsia Pharmaceuticals US Inc | 3 | $67 |
| Johnson & Johnson | 3 | $64 |
| Dexcom, Inc. | 2 | $48 |
| Amgen | 2 | $40 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Corium, LLC | 1 | $22 |
| IBSA Pharma Inc. | 1 | $20 |
| Optinose US, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
How this compares
$6,301,890 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Miami
- Keila HooverMiami$33.7M
- Jorge CasoMiami$22.6M
- David WyattMiami$13.7M
- Jose CardenasMiami$13.2M
- Lazaro GarciaMiami$10.3M
- Ibrahim Menendez PerezMiami$8.9M
- Aniel Navarro MarinMiami$7.3M
- Gilberto SecoMiami$6.8M
- Eddy CapoteMiami$6.2M
- Erick JuarezMiami$5.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.